Loading...
Indian Pharmaceutical Exporter · Respiratory Specialist · $170.5K Total Trade · DGFT Verified
Saviour International is an Indian pharmaceutical exporter with a total trade value of $170.5K across 2 products in 2 therapeutic categories. Based on 16 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Formoterol ($117.2K), Semaglutide ($53.3K), .
Saviour International, established in 2019, is a New Delhi-based pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company operates under the Goods and Services Tax (GST) number 07ADGFS8871E1ZP, with its registered office located at B No. B-179, F/F DDA Shed, Okhla Phase-1, New Delhi, Delhi, 110020, India. As of the latest available data, Saviour International employs approximately 15 staff members. The company's official website is saviourpharma.com.
Saviour International's product portfolio is diverse, encompassing over 70 items across various therapeutic categories. These include anti-cancer medicines, pharmaceutical ointments, tablets, injections, and capsules. Notable products include Anastrozole Tablets, Erlotinib Tablets IP, and Tenofovir Disoproxil Fumarate Tablets IP 300mg. The company's focus on high-quality, safe, and effective products at competitive prices has facilitated partnerships with over seven countries, reflecting its commitment to global healthcare solutions.
Saviour International operates across 2 therapeutic categories, with Respiratory (68.7%), Advanced Diabetes Medications (31.3%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Respiratory
1 products · 68.7% · $117.2K
Advanced Diabetes Medications
1 products · 31.3% · $53.3K
Saviour International exports 2 pharmaceutical products across 2 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Formoterol | Respiratory | $117.2K | 12 | 0.2% |
Headquarters, ownership, manufacturing facilities, and key leadership
Saviour International, established in 2019, is a New Delhi-based pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company operates under the Goods and Services Tax (GST) number 07ADGFS8871E1ZP, with its registered office located at B No. B-179, F/F DDA Shed, Okhla Phase-1, New Delhi, Delhi, 110020, India. As of the latest available data, Saviour International employs approximately 15 staff members. The company's official website is saviourpharma.com.
Saviour International's product portfolio is diverse, encompassing over 70 items across various therapeutic categories. These include anti-cancer medicines, pharmaceutical ointments, tablets, injections, and capsules. Notable products include Anastrozole Tablets, Erlotinib Tablets IP, and Tenofovir Disoproxil Fumarate Tablets IP 300mg. The company's focus on high-quality, safe, and effective products at competitive prices has facilitated partnerships with over seven countries, reflecting its commitment to global healthcare solutions.
Saviour International operates a WHO-GMP approved manufacturing facility located in Gujarat, India. This state-of-the-art plant is designed to meet global standards set by the World Health Organization's Good Manufacturing Practices. Equipped with advanced HVAC systems, the facility ensures optimal cleanliness and humidity control, providing a pristine environment for pharmaceutical and nutraceutical production. Dedicated spaces for raw materials, packing, manufacturing, quality control, and storage streamline processes to deliver high-quality, affordable medicines.
| 2 | Semaglutide | Advanced Diabetes Medications | $53.3K | 4 | 1.1% | 14 |
Saviour International exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $170.5K. The top category is Respiratory (68.7% of portfolio), followed by Advanced Diabetes Medications (31.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Shipment-level records, pricing & buyer contacts for Saviour International.
Request DemoSaviour International is managed by Ms. Gunjan, who serves as the Manager of the company. While specific details about other key executives, such as the CEO, CFO, and other leadership roles, are not publicly disclosed, the company's leadership is committed to upholding high standards of quality and operational excellence.
Regulated market presence, emerging market penetration, and geographic strategy
Saviour International's export activities are primarily focused on markets in Africa, the Middle East, and parts of Asia. The company has established trade relationships with countries such as Somalia, Hong Kong, and the United Arab Emirates. While specific regulatory filings and approvals in the United States, European Union, United Kingdom, Australia, and Japan are not detailed in the available sources, the company's adherence to WHO-GMP standards suggests a commitment to meeting international regulatory requirements. This adherence is crucial for accessing and maintaining market presence in these regulated regions.
Saviour International has made significant inroads into emerging markets, particularly in Africa and the Middle East. The company's export data indicates shipments to countries such as Somalia and the United Arab Emirates. While specific information regarding WHO prequalification is not available, the company's WHO-GMP certification enhances its credibility and potential for market access in these regions. This certification is a critical factor for gaining entry into emerging markets, as it demonstrates compliance with international quality standards.
Saviour International's export strategy appears to be concentrated in select markets, including Africa and the Middle East. This focused approach may present opportunities for deep market penetration and specialization. However, the lack of diversification into other regions could expose the company to risks associated with over-reliance on specific markets. To mitigate potential risks and capitalize on global opportunities, Saviour International may consider expanding its geographic footprint and exploring new markets.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Specific information regarding Saviour International's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's WHO-GMP certification indicates a commitment to quality standards recognized internationally, which is a positive indicator for potential FDA interactions. However, without explicit FDA approvals or registrations, the company's products may face challenges in entering the U.S. market.
Saviour International's manufacturing facility in Gujarat, India, is WHO-GMP approved, ensuring compliance with global manufacturing standards. While the company emphasizes its commitment to quality and has achieved WHO-GMP certification, specific details regarding EU GMP certification are not provided in the available sources. EU GMP certification is essential for accessing European markets, and obtaining this certification could enhance the company's competitiveness in the region.
Saviour International operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's WHO-GMP certification aligns with CDSCO's standards for pharmaceutical manufacturing. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. However, the company's adherence to international quality standards suggests compliance with Indian regulatory requirements.
There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Saviour International. The absence of such regulatory actions indicates that the company maintains a positive compliance record with regulatory authorities. This is a favorable aspect for potential partners and customers evaluating the company's reliability and adherence to regulatory standards.
Market share comparison, key differentiators, and strategic analysis
Saviour International operates in a competitive pharmaceutical export market, with numerous companies offering similar products across overlapping therapeutic categories. While specific market share data is not available, the company's focus on high-quality, safe, and effective products at competitive prices positions it favorably in the market. To enhance its competitive edge, Saviour International may consider differentiating its product offerings, expanding its geographic reach, and strengthening its regulatory compliance to meet the diverse needs of global markets.
Saviour International's commitment to quality is a significant differentiator in the pharmaceutical export market. The company's WHO-GMP certification reflects adherence to international manufacturing standards, ensuring the safety and efficacy of its products. Additionally, the company's focus on a diverse product portfolio across various therapeutic categories allows it to cater to a wide range of healthcare needs, enhancing its appeal to a broad customer base.
Saviour International's current strategic direction emphasizes the export of finished pharmaceutical formulations, with a focus on markets in Africa and the Middle East. The company's adherence to WHO-GMP standards and its diverse product portfolio position it well for future growth. To capitalize on emerging opportunities, Saviour International may consider expanding its product offerings, obtaining additional certifications such as EU GMP, and exploring new markets to diversify its revenue streams and reduce dependence on specific regions.
Track record assessment, certifications to verify, and pre-order checks
Saviour International has demonstrated a consistent track record in exporting pharmaceutical products, with 16 shipments totaling $170,000 USD between 2022 and 2026. The company's focus on high-quality products and adherence to international standards suggest reliability and consistency in its supply chain operations. However, the concentration of exports in a limited number of products and markets indicates potential risks associated with over-reliance on specific products and regions. Diversifying the product portfolio and expanding into new markets could enhance the company's resilience and growth prospects.
Importers should verify the following certifications when considering Saviour International as a supplier:
When conducting due diligence on Saviour International, importers should consider the following steps:
By following this checklist, importers can make informed decisions and establish successful partnerships with Saviour International
Saviour International exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Formoterol ($117.2K), Semaglutide ($53.3K). Total export value is $170.5K.
Saviour International's total pharmaceutical export value is $170.5K, based on 16 verified shipments recorded in Indian Customs (DGFT) data.
Saviour International exports across 2 therapeutic categories. The largest are Respiratory (68.7%, 1 products), Advanced Diabetes Medications (31.3%, 1 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Products Tracked
2 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.